IL-4Rα antagonist (Stapokibart) in refractory palmoplantar pustulosis: a case report and literature review of Th2-targeted therapies
Frontiers in Immunology · 13.08.2026 · 17
DOI: 10.3389/fimmu.2026.1851685 ↗Kurz gefasst
Fallbericht in der Zeitschrift Frontiers in Immunology, online erschienen am 13.08.2026. Verfasst von Yuqi Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China. Hauptthemen laut MEDLINE: Th2 Cells, Psoriasis, Interleukin-4 Receptor alpha Subunit, Antibodies, Monoclonal. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Traditionally associated with Th17-mediated pathways, palmoplantar pustulosis (PPP) is a persistent inflammatory dermatosis limited to the palms and soles. However, therapeutic responses to IL-17/IL-23 suppression are often limited, indicating significant immunological heterogeneity. There is growing evidence that type 2-associated immunological pathways may have a role in the persistence of disease in some patients. Herein, we report a 40-year-old woman with refractory PPP who had no personal or familial history of psoriasis or atopy. She was treated with stapokibart, an IL-4Rα monoclonal antibody that inhibits IL-4/IL-13 signaling, and experienced a rapid and long-lasting remission. Previous treatments, such as topical corticosteroids, retinoids, and Tripterygium wilfordii, were ineffective. Lesional skin exhibited moderate phosphorylated STAT6 positivity in scattered inflammatory infiltrates, independent of CD4+ T-cell presence, indicating engagement of canonical IL-4/IL-13 signaling at the tissue level, despite normal serum IgE levels and the lack of peripheral or tissue eosinophilia. The context-dependent clinical significance of Th2 pathway regulation in PPP is highlighted by a systematic literature review combined with our case. In non-atopic individuals, who frequently have noticeable pruritus despite unimpressive systemic atopic indicators, blockade of IL-4/IL-13 signaling has resulted in significant clinical relief. On the other hand, it has also been observed that blocking Th2-related pathways, such as IL-4/IL-13, IL-5, or IL-31, paradoxically causes PPP, highlighting the bidirectional and context-dependent significance of Th2 signaling in disease pathogenesis. Together with clinical characteristics like excessive pruritus, tissue-level Th2 activation may offer useful indicators to direct precision treatment in this diverse illness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
- School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Zitieren
APA
Zhang, Y., He, Y., Leng, R., Liu, W., Zhou, X., & Yang, J. (2026). IL-4Rα antagonist (Stapokibart) in refractory palmoplantar pustulosis: a case report and literature review of Th2-targeted therapies. Frontiers in Immunology, 17. https://doi.org/10.3389/fimmu.2026.1851685
Vancouver
Zhang Y, He Y, Leng R, Liu W, Zhou X, Yang J. IL-4Rα antagonist (Stapokibart) in refractory palmoplantar pustulosis: a case report and literature review of Th2-targeted therapies. Frontiers in Immunology. 2026;17. doi:10.3389/fimmu.2026.1851685
BibTeX
@article{Zhang2026,
author = {Zhang, Yuqi and He, Yuexi and Leng, Rao and Liu, Wei and Zhou, Xiyuan and Yang, Jianing},
title = {IL-4Rα antagonist (Stapokibart) in refractory palmoplantar pustulosis: a case report and literature review of Th2-targeted therapies},
journal = {Frontiers in Immunology},
year = {2026},
volume = {17},
doi = {10.3389/fimmu.2026.1851685}
}
EUVIMED